SCYNEXIS Q3 net loss $29.6M ($0.62/sh), BREXAFEMME rev $1.6M; CEO to retire; PDUFA Nov 30

SCYNEXIS INC

2022-Q3 EPS reported -$1.18 revenue$3,567,000

Q3 2022 net loss $29.6M vs $0.6M loss in Q3 2021; basic loss per share $0.62 vs $0.02.
BREXAFEMME net revenue $1.6M (up 23% QoQ); 5,785 total prescriptions written, up 13% vs Q2.
Cash, equivalents and short-term investments $96.1M; projected runway into Q2 2024.
CEO Marco Taglietti to retire Dec 31, 2022; David Angulo (CMO) to become CEO effective Jan 1, 2023.
PDUFA date Nov 30, 2022 for BREXAFEMME sNDA for prevention of recurrent VVC; company seeking commercialization partner.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

SCYNEXIS INC reported the third quarter ended September 30, 2022 results: revenue $1.6 million.

Period: the third quarter ended September 30, 2022
Revenue: $1.6 million
Result: reported results

Exact text from the filing

the Board effective January 1, 2023. • BREXAFEMME ® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3 2022, compared to $1.3 million in Q2 2022. • Coverage for BREXAFEMME increased to 130 million, or 70% of commercially insured lives, with the addition of a major national

View on SEC.gov

Browse all earnings releases →

SCYNEXIS INC filing history →

Source: SEC EDGAR

accession 0000950170-22-023510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.